The future of antibody therapy starts here.

The problem

The antibody industry lacks the tools to efficiently analyze every possible candidate. This leads to ‘passable’ drugs that suffer from limitations in dosing, administration, safety and efficacy.

The solution

OCMS rapidly discovers novel, de-risked, fast-follower, best-in-class antibodies with a tunable target product profile optimized for binding, immunogenicity, stability, and function.